1. வினையூக்கி & ராம்ப்-அவேர் தாக்கக் கணக்கீடு

Borosil Scientific's board approved a greenfield backward-integration capex of up to Rs 70 Cr to establish a 20 MT/day Borosilicate 3.3 glass tubing furnace at its Bharuch facility. - Capex Size vs Base: Rs 70 Cr represents ~14.6% of TTM revenue (Rs 478 Cr) and ~71.6% of current net fixed assets (Rs 97.8 Cr). Combined with the Rs 60 Cr glassware expansion approved in September 2026, total ongoing capex sits at Rs 130 Cr. - Execution Timeline: Target commercial production is scheduled for March 31, 2028 (~17 months / 1.5 years). Hence, Year-1 revenue uplift is 0.0%. - Steady-State Economics (FY29E): At full capacity (20 MT/day ~ 7,300 MT/year), output will primarily serve as captive raw material for laboratory and pharmaceutical glassware, displacing imported tubing, with surplus sold to third-party scientific converters. Assuming Rs 50-60 Cr equivalent output value: - Captive replacement reduces raw material costs (currently 35.8% of sales). - Steady-state revenue uplift (merchant sales + higher downstream capacity): ~12% (Rs ~55-60 Cr). - Margin expansion: Estimated 150-200 bps boost to EBITDA margins due to import substitution and energy efficiencies. - At steady state, EBITDA increases by ~Rs 12-14 Cr. After incremental depreciation (~Rs 5.5 Cr at 8%) and tax, incremental PAT is ~Rs 6.0 Cr, delivering an estimated EPS uplift of ~20% on FY26 base.

2. Industry Capital Intensity & Structural CAGR

Specialty glass manufacturing is capital-intensive and operationally demanding. Borosilicate 3.3 glass melting requires high-temperature continuous furnaces, uninterrupted power/gas, and high technical precision to meet pharma and laboratory standards. Industry growth tracks pharmaceutical R&D, chemical QA/QC labs, and healthcare spending, compounding structurally at ~10% CAGR.

3. Multibagger Quality & Fundamental Profile

• Growth & Acceleration: Revenue expanded from Rs 396 Cr (FY24) to Rs 467 Cr (FY26) (~8.6% CAGR). Q1 FY27 showed a recovery (+11.2% YoY), but Q2 FY27 standalone showed modest top-line growth (+4.7%) and PAT decline (-16.9%).
• Margins & ROCE: OPM stands at 13.7%, with ROCE at 14.0%. The business is high quality with a reputable brand moat ('Borosil') and strong domestic distribution.
• Balance Sheet & Ownership: Zero net debt (Debt of Rs 1 Cr vs Net Worth of Rs 462 Cr) gives the company complete financial flexibility to absorb Rs 130 Cr of multi-year capex without equity dilution. Promoter stake has risen to 68.27%.

4. Valuation & Calibrated Scenarios (24-36 Month Horizon)

Current price of Rs 109.4 discounts Borosil Scientific at 22.6x trailing EPS (Rs 4.85), below peer median P/E of 33.9x. - Base Case (+35% upside to ~Rs 148): Commissioning concludes by Q1 FY29. FY29 EPS reaches Rs 6.50 on backward integration cost savings and LabQuest expansion. P/E multiples re-rate moderately to 23x. - Bull Case (+75% upside to ~Rs 191): Both the Rs 60 Cr glassware capacity expansion (7x volume) and Rs 70 Cr tubing furnace ramp smoothly. Export share rises above 20%, OPM expands to 16.5%, EPS scales to Rs 7.65, with valuation re-rating to 25x. - Bear Case (-20% downside to ~Rs 88): Delays in furnace commissioning, escalating energy/raw material costs, and CWIP drag push ROCE down toward 10-11%. Multiple compresses to 18x on depressed FY28 earnings.

5. தீர்ப்பின் காரணம்

The capex announcement is strategically sound and enhances long-term moats via raw material self-reliance. However, because commercialization is slated for March 2028, this catalyst is a multi-year gestation project that will provide zero earnings relief over the next 12-18 months while depressing asset turnover and ROCE in the interim. Coupled with moderate single-digit near-term top-line momentum, BOROSCI qualifies as a POSSIBLE compounder rather than a rapid near-term multibagger.

Investment Analysis: Borosil Scientific Limited (BOROSCI)

பகுப்பாய்வு தேதி: 2026-09-22
Current Price: ₹120.0 | Market Cap: ₹1,061 Cr | Trailing P/E: 24.7x | P/B: 2.3x
TTM Revenue: ₹478 Cr | TTM PAT: ₹43 Cr | TTM EPS: ₹4.85 | ROCE: 14.0%

1. Ramp-Aware Catalyst Impact Math

On September 22, 2026, Borosil Scientific approved a ₹60 crore brownfield capex to expand specific glassware manufacturing capacity from ~15 lakh units to ~108 lakh units per annum (+620% unit volume) at its Bharuch, Gujarat facility. The expansion is slated for commercial launch by March 2027.

• Capital Context: Current Net Fixed Assets stand at ~₹97.8 Cr. A ₹60 Cr capex expands the company's fixed asset base by ~61%. The existing facility is running near ceiling at ~87% utilization.
• Asset Turnover & Revenue Potential: In specialized scientific/pharma glassware, historical gross fixed asset turnover ranges between 1.5x and 1.8x. At an asset turn of 1.6x, ₹60 Cr capex generates ~₹95 Cr to ₹100 Cr in peak incremental annual revenue.
• Phased Ramp Profile:
• FY27 (Year 0): Zero revenue contribution; project under execution through March 2027.
• FY28 (Year 1 of Operations): Trial runs and initial qualification with customer Borosil Limited. Assuming 40% capacity utilization, incremental revenue is estimated at ~₹38 Cr (+8.0% uplift over TTM revenue of ₹478 Cr).
• FY29 (Year 2 of Operations): Ramp to 70% utilization yields ~₹68 Cr incremental revenue (+14.2% uplift).
• FY30 (Steady State): Full ramp at 85-90% utilization generates ~₹95 Cr incremental revenue (+20.0% uplift).
• Margin & EPS Flow-Through:
• Glassware supplied captively to Borosil Limited will likely earn standard contracted EBITDA margins of ~13.5% (yielding ~₹12.8 Cr incremental EBITDA at full ramp).
• Deducting depreciation on ₹60 Cr capex (~₹4.8 Cr/year at 8%) and minor working capital financing/tax (~₹2.0 Cr), incremental steady-state PAT is ~₹6.0 Cr to ₹7.5 Cr.
• On a TTM PAT of ₹43 Cr, this translates to an incremental EPS boost of ~₹0.85 per share (+17.5% EPS uplift), taking baseline EPS from ₹4.85 to ~₹5.70-₹6.20 by FY29/FY30 (excluding organic growth from the core business).

2. தொழில்துறைச் சூழல் & மூலதனத் தீவிரம்

• Capital Intensity: MEDIUM. Precision scientific glassware and lab instrumentation require dedicated high-temperature furnaces, annealing lehrs, and clean-room packaging, but do not feature the crushing capital intensity of primary container glass or float glass.
• Execution Difficulty: MEDIUM. The company possesses established operating history in Bharuch (formerly Klass Pack). However, manufacturing pharma-grade and scientific glassware requires strict dimensional tolerance and compliance with international pharmacopeia standards.
• Industry Growth Outlook: India's laboratory research and pharmaceutical testing equipment sector is compounding at ~10.0% to 11.0% annually, driven by domestic R&D spending and contract research (CROs).

3. Multibagger Quality & SEPA Screening

• Earnings & Growth Track Record: C-grade. FY24 revenue of ₹396 Cr grew to ₹438 Cr in FY25 (+10.5%) and ₹467 Cr in FY26 (+6.7%). Top-line growth is sub-15%, failing classic Minervini acceleration criteria.
• Quarterly Lumps: PAT is highly volatile (Q4 FY26 spiked to ₹27.0 Cr, whereas Q1 FY27 delivered ₹4.36 Cr, and Q1 FY26 had a loss of ₹4.21 Cr due to a ₹6.61 Cr labor dispute settlement). Much of the trailing PAT is weighted in single blowout quarters.
• Balance Sheet & Moat: Strong. Debt is virtually nil (₹1 Cr), Net Worth is ₹462 Cr, and promoter holding is steady at 68.1%. The "Borosil" brand enjoys pristine recall in lab glassware with high switching costs in certified testing labs.
• Capital Efficiency: Trailing ROCE of 14.0% and ROE of ~7.4% are respectable but not high enough to drive explosive, non-linear compounding on their own.

4. மதிப்பீட்டுச் சூழ்நிலைகள் (24-36 மாத கால எல்லை)

• Base Case (+38% upside to ₹165):
• Capex commences operations by Q1 FY28 and ramps to 75% by FY29.
• Combined revenue reaches ~₹590 Cr by FY29 (core growing at 8% + ₹65 Cr capex contribution).
• OPM normalizes at 14.0%; PAT reaches ~₹55 Cr (EPS ~₹6.22 on current share count).
• Sustaining a trailing multiple of 26.5x yields a target price of ~₹165.
• Bull Case (+72% upside to ₹206):
• Rapid ramp-up driven by accelerated exports and strong uptake of higher-margin 'LabQuest' instrumentation.
• Operating leverage expands OPM to 16.0%; FY29 PAT reaches ~₹65 Cr (EPS ~₹7.35).
• P/E re-rates toward the peer median (31.6x) to 28.0x, yielding ₹206.
• Bear Case (-25% downside to ₹90):
• Execution of the ₹250 Cr approved fundraise causes significant dilution (~20-25% fresh equity).
• Delays in furnace commissioning or unfavorable transfer pricing with Borosil Limited keeps PAT stagnant near ₹40-42 Cr.
• Multiple de-rates to 20x on diluted EPS of ₹4.50, driving the stock down to ₹90.

5. Final Verdict & Rationale

Borosil Scientific's ₹60 Cr capex is a sound, self-funded operational expansion that addresses clear capacity bottlenecks (87% utilization) for an established off-taker. However, from a multibagger perspective, it falls short of being a high-conviction candidate: 1. The expansion is incremental (+20% steady-state revenue over 3 years) rather than transformational. 2. The overarching revenue growth trajectory of 8-11% is characteristic of a steady, mature niche rather than a high-velocity growth leader. 3. The approved ₹250 Cr capital raise creates an overhang of per-share equity dilution.

Verdict: POSSIBLE (Score: 43/100). The stock offers solid downside protection due to a pristine balance sheet, but requires faster organic instrumentation growth or high-margin export traction to unlock multibagger returns.